Portnoy David's Form 4 filing
Cryo Cell International Inc (CCEL) · filed Sep 18, 2025
- Accession no.
- 0001193125-25-207528
- Filed
- Sep 18, 2025
- Trade date
- Sep 16-18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market purchases total $76.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Portnoy DavidCIK 0001315416 | Director, Officer (Chairman, Co-CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | Common Stock | PPurchaseAcquired | +6,449 | $4.46F1 | +$28,762.54 | 818,369 | Direct | |
| Sep 17, 2025 | Common Stock | PPurchaseAcquired | +5,564 | $4.43F2 | +$24,648.52 | 823,933 | Direct | |
| Sep 18, 2025 | Common Stock | PPurchaseAcquired | +3,411 | $4.46F3 | +$15,213.06 | 827,344 | Direct | |
| Sep 18, 2025 | Common Stock | PPurchaseAcquired | +1,751 | $4.49 | +$7,861.99 | 161,833 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.40 to $4.47, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.41 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.45 to $4.50, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.